News Release
Quartesian Signs Enterprise License Agreement to Offer Complete Access Across Markets to Medidata’s Industry Leading Cloud Platform
Known for delivering “Clinical Data Your Way” for early and late-stage clinical studies, Quartesian will build on its expertise around Medidata Rave®, the world’s leading solution for capturing, managing and reporting patient data, to now offer a broader set of data capture and data management capabilities to all of its customers.
The company completed training and has accreditations to implement and market Medidata products; including Rave, Medidata Coder®, Medidata TSDV, Medidata Balance®, which unifies randomization, trial supply management and EDC into one system and Medidata Patient Cloud ePRO, a mobile app for patient reported outcomes. Over the last three years, Quartesian has seen a significant increase in the demand for these solutions. With its growing expertise in key Medidata technology for clinical research, Quartesian is consistently able to rapidly deploy high quality, cost-efficient clinical data services for many of its life sciences customers and CRO partners.
"Signing this enterprise agreement has been the culmination of over
three years of experience and partnering with Medidata. We are excited
about being able to offer the complete Medidata suite across all
Quartesian’s market segments. Whether it is phase I or generic programs
or larger phase II and III studies, Quartesian can offer the industry’s
leading data capture system combined with our low-cost EDC build, data
management and biostatistical programming," said
“We are delighted that Quartesian is benefitting from Medidata’s unified
platform and advanced analytics,” said
About Medidata
Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 950 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers—from study design and planning through execution, management and reporting.
About Quartesian
View source version on businesswire.com: http://www.businesswire.com/news/home/20171213005581/en/
Source: Medidata
Medidata
Investor:
Betsy Frank, +1 917-522-4620
bfrank@mdsol.com
or
Anthony
D’Amico, +1 732-767-4331
adamico@mdsol.com
or
Media:
Erik
Snider, +1 646-362-2997
esnider@mdsol.com
or
Quartesian
Media:
Stephen
Boccardo, +609-454-3312
Sr. VP Business Development and Commercial
Strategy
stephen.boccardo@quartesian.com